MCL1 and neoplasm: To assess whether Mcl-1 contributed to the survival of senescent tumor cells, we treated them with S63845, a potent Mcl-1 inhibitor52,53 in parallel to the Bcl2 inhibitor Navitoclax (ABT263)50,51.